Quarterly report [Sections 13 or 15(d)]

Consolidated Statement of Stockholders' Equity

v3.25.1
Consolidated Statement of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2023   81,818      
Balance at beginning of period at Dec. 31, 2023 $ 686,265 $ 8 $ 808,575 $ (3,791) $ (118,527)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued pursuant to equity awards, net (in shares)   1,249      
Common stock issued pursuant to equity awards, net 8,777   8,777    
Stock-based compensation 17,032   17,032    
Other comprehensive income (loss) (1,782)     (1,782)  
Net loss (72,309)       (72,309)
Balance at end of period (in shares) at Mar. 31, 2024   83,067      
Balance at end of period at Mar. 31, 2024 $ 637,983 $ 8 834,384 (5,573) (190,836)
Balance at beginning of period (in shares) at Dec. 31, 2024 84,613 84,613      
Balance at beginning of period at Dec. 31, 2024 $ 516,283 $ 8 886,823 (6,823) (363,725)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued pursuant to equity awards, net (in shares)   1,761      
Common stock issued pursuant to equity awards, net 2,877 $ 1 2,876    
Stock-based compensation 22,871   22,871    
Other comprehensive income (loss) 857     857  
Net loss $ (49,713)       (49,713)
Balance at end of period (in shares) at Mar. 31, 2025 86,374 86,374      
Balance at end of period at Mar. 31, 2025 $ 493,175 $ 9 $ 912,570 $ (5,966) $ (413,438)